John L. Slebir, Senior Vice President and General Counsel, has exclusively traded shares of Dynavax Technologies (DVAX) over 24 transactions, all of which were sales totaling $651,964.62 with no recorded purchases. His most significant disposals occurred on December 24, 2025, when he sold shares worth $499,880.76, followed by earlier transactions on February 18, 2025 ($69,278.94), February 13, 2025 ($59,744.52), and February 10, 2025 ($23,060.40). The remaining transactions, primarily marked as derivative dispositions (code "D") or acquisitions (code "A"), involved no reported dollar value, suggesting they may represent option exercises, awards, or other non-cash adjustments.
Slebir’s trading history reveals a clear divestment pattern, with all monetized sales occurring in 2025 and concentrated in February and December of that year. The absence of any buy transactions indicates a consistent reduction in his position in Dynavax, though the filings do not specify whether these sales were part of prearranged trading plans. Notably, the bulk of the proceeds came from the late-2025 transaction, which accounted for over 76% of his total sell value. While the filings document routine regulatory disclosures, they reflect a directional trend of decreasing equity exposure to DVAX over time.
AI-assisted summary